Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 64Gynecologic 3Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Sarcoma 1Plasma cell 1Lymphoid 1Dermatologic 1CNS 1

Conditions

Carcinoma, Renal Cell 13Prostatic Neoplasms 8Kidney Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Ovarian Neoplasms 4Neoplasms 4Colorectal Neoplasms 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Neoplasm Metastasis 3Melanoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urologic Neoplasms 1Urethral Neoplasms 1Thrombocytosis 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

pembrolizumab 33Nivolumab 15atezolizumab 9Cyclophosphamide 7Paclitaxel 6Ipilimumab 6spartalizumab 5fludarabine 5Docetaxel 5durvalumab 4avelumab 4Immune Checkpoint Inhibitors 4Carboplatin 4olaparib 3cemiplimab 3cabozantinib 3Specimen Handling 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Leucovorin 3Interleukin-2 3Gemcitabine 3Fluorouracil 3Cisplatin 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3sacituzumab govitecan 2obinutuzumab 2lenvatinib 2epacadostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Capecitabine × Genitourinary × Clear all
NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡